Pancreatic Cancer Research

ResearcherTongji UniversityActive in the last 2 years

Maoquan Li

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-2087-6769; OpenAlex author ID A5102020727. Sources: OpenAlex.

Their work

Papers
9 (first author 1, last author 3)
Trials
0
Grants
0
Labs led
1
Collaborators
31
Papers, trials and grants by year

2016: 1 paper · 2017: none · 2018: none · 2019: none · 2020: 1 paper · 2021: 3 papers · 2022: 1 paper · 2023: none · 2024: 2 papers · 2025: 1 paper

Papers 9

  1. Clinical significance of risk factor analysis in pancreatic cancer by using supervised model of machine learning. Last author DOI 10.3389/fmed.2025.1551926↗
  2. FTO Knockdown-Mediated Maturation of miR-383-5p Inhibits Malignant Advancement of Pancreatic Cancer by Targeting ITGA3. Last author DOI 10.1007/s10528-023-10560-0↗
  3. Guidelines for permanent iodine-125 seed interstitial brachytherapy for pancreatic cancer (2023 edition): The Chinese expert consensus workshop report. Co-author DOI 10.4103/jcrt.jcrt_2368_23↗
  4. GAS41 mediates proliferation and GEM chemoresistance via H2A.Z.2 and Notch1 in pancreatic cancer. Co-author DOI 10.1007/s13402-022-00675-8↗
  5. Clinical practice guidelines for the interventional treatment of advanced pancreatic cancer (5th edition). Co-author DOI 10.1016/j.jimed.2021.08.001↗
  6. Transcatheter Arterial Infusion Combined With Radioactive Particles in the Treatment of Advanced Body/Tail Pancreatic Cancer: A Retrospective Cohort Study. Co-author DOI 10.1097/mpa.0000000000001851↗
  7. Chinese expert consensus of image-guided irreversible electroporation for pancreatic cancer. Co-author DOI 10.4103/jcrt.jcrt_1663_20↗
  8. In advanced pancreatic cancer: The value and significance of interventional therapy. First author DOI 10.1016/j.jimed.2020.07.002↗
  9. MicroRNA-182 promotes pancreatic cancer cell proliferation and migration by targeting β-TrCP2. Last author DOI 10.1093/abbs/gmw105↗

Closest collaborators

The 25 strongest of 31 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Shilong Han · 4 shared papers, 2016–2024 · strength 0.57
  2. Xiaoping Zhang · 3 shared papers, 2016–2022 · strength 0.31
  3. Wei Zhang · 1 shared paper, 2024 · strength 0.26
  4. Amir Sherchan · 1 shared paper, 2025 · strength 0.25
  5. Chaosu Hu · 1 shared paper, 2020 · strength 0.24
  6. Chengli Li · 2 shared papers, 2021–2024 · strength 0.23
  7. Lizhi Niu · 2 shared papers, 2021–2024 · strength 0.23
  8. Rui Liu · 1 shared paper, 2022 · strength 0.15
  9. Xiaojun Zhang · 1 shared paper, 2022 · strength 0.15
  10. Zhongmin Wang · 1 shared paper, 2024 · strength 0.15
  11. Hongxin Niu · 1 shared paper, 2024 · strength 0.15
  12. Yuliang Li · 1 shared paper, 2024 · strength 0.15
  13. Baodong Gai · 1 shared paper, 2024 · strength 0.15
  14. Bin Liu · 1 shared paper, 2024 · strength 0.15
  15. Hong Zhao · 1 shared paper, 2024 · strength 0.15
  16. Fujun Zhang · 1 shared paper, 2024 · strength 0.15
  17. Yuliang Li · 1 shared paper, 2021 · strength 0.10
  18. Wujie Wang · 1 shared paper, 2021 · strength 0.10
  19. Jun Chen · 1 shared paper, 2021 · strength 0.10
  20. Huirong Xu · 1 shared paper, 2021 · strength 0.10
  21. Yingtian Wei · 1 shared paper, 2021 · strength 0.08
  22. Tianan Jiang · 1 shared paper, 2021 · strength 0.08
  23. Yinying Lu · 1 shared paper, 2021 · strength 0.08
  24. Liwei Wang · 1 shared paper, 2021 · strength 0.08
  25. Ming Kuang · 1 shared paper, 2021 · strength 0.08

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.